Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Losartan Potassium NDC 71610-224 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Bottle Label 25 mg - 71610 0224 30
Aphena Pharma Solutions - TN - Aphena
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
This is a comparison between two medications, Atenolol and Losartan Potassium, showing a 13% reduction in the risk of primary endpoint (not specified what that is) in patients taking Losartan Potassium. The study's duration was 66 months and was carried out in monthly intervals, with data recorded at each interval.*
Figure 2 - spl image3 figure2
This text presents information regarding medication substitution. Atenolol can be replaced by Losartan Potassium, with an adjusted risk reduction of 25% and a p-value of 0.001. Additionally, there is a table showing the percentage of patients with fatal/non-fatal strokes over time intervals ranging from 6 to 66 months.*
Figure 3 - spl image4 figure3
The text describes demographic subgroup analysis for primary endpoint events in patients taking either Losartan Potassium or Atenolol. The primary composite stroke events were analyzed across different subgroups such as age, gender, race, diabetes, and history of CVD. The results of the analysis are presented in tabular form, along with Hazard Ratios (95%CI) and event rates for each subgroup. The table also includes a legend to interpret the symbols used in the table, and a note that the analysis is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - spl image5 figure4
This is a graph showing the percentage of patients who experienced an event over a course of 48 months while taking either Losartan Potassium or a placebo medication. The risk reduction with Losartan Potassium compared to placebo is 16.1%, which was found to be statistically significant with a p-value of 0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.